Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model

ACS Chemical Neuroscience

Volumn 6, Issue 8, 2015, Pages 1393-1399

  Gerenu, Gorka ^a   Liu, Kai ^b   Chojnacki, Jeremy E ^b   Saathoff, John M ^b   Martínez Martín, Pablo ^c   Perry, George ^d   Zhu, Xiongwei ^a   Lee, Hyoung Gon ^a   Zhang, Shijun ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Instituto de Salud Carlos III   (Spain)

^d University of San Antonio   (United States)

Author keywords

Alzheimers disease; curcumin; Hybrid compounds; melatonin; neuroprotectants

Indexed keywords

5 (4 HYDROXY PHENYL) 3 OXO PENTANOIC ACID [2 (5 METHOXY 1H INDOL 3 YL) ETHYL] AMIDE; AMIDE; AMYLOID BETA PROTEIN; CURCUMIN; MELATONIN; NEUROPROTECTIVE AGENT; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; COUMARIN DERIVATIVE; INDOLE DERIVATIVE; MULTIENZYME COMPLEX; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; VALERIC ACID DERIVATIVE; Z-CM-I-1;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL ACTIVATION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LONG TERM CARE; MICROGLIA; MITOCHONDRION; MOUSE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY CHAIN; ANIMAL; BRAIN; CHEMICAL STRUCTURE; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE; WESTERN BLOTTING;

MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; BRAIN; COUMARINS; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; FEMALE; IMMUNOHISTOCHEMISTRY; INDOLES; MELATONIN; MICE, TRANSGENIC; MICROGLIA; MOLECULAR STRUCTURE; MUTATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PENTANOIC ACIDS; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84934968246     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00082     Document Type: Article

References (49)

1. Alzheimers Association (2013) 2013 Alzheimers Disease Facts and Figures Alzheimers Dementia 9, 208-245
2. Hardy, J. A. and Higgins, G. A. (1992) Alzheimers disease: the amyloid cascade hypothesis Science 256, 184-185
3. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I. R., McGeer, P. L., OBanion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000) Inflammation and Alzheimers disease Neurobiol. Aging 21, 383-421
4. Castellani, R., Hirai, K., Aliev, G., Drew, K. L., Nunomura, A., Takeda, A., Cash, A. D., Obrenovich, M. E., Perry, G., and Smith, M. A. (2002) Role of mitochondrial dysfunction in Alzheimers disease J. Neurosci. Res. 70, 357-360
5. Zhu, X., Su, B., Wang, X., Smith, M. A., and Perry, G. (2007) Causes of oxidative stress in Alzheimer disease Cell. Mol. Life Sci. 64, 2202-2210
6. Carreiras, M. C., Mendes, E., Perry, M. J., Francisco, A. P., and Marco-Contelles, J. (2013) The multifactorial nature of Alzheimers disease for developing potential therapeutics Curr. Top. Med. Chem. 13, 1745-1770
7. Frautschy, S. A. and Cole, G. M. (2010) Why pleiotropic interventions are needed for Alzheimers disease Mol. Neurobiol. 41, 392-409
8. Chojnacki, J. E., Liu, K., Yan, X., Toldo, S., Selden, T., Estrada, M., Rodriguez-Franco, M. I., Halquist, M. S., Ye, D., and Zhang, S. (2014) Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimers disease by hybridization of curcumin and melatonin ACS Chem. Neurosci. 5, 690-699
9. Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., and Borchelt, D. R. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies Biomol. Eng. 17, 157-165
10. Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics Science 297, 353-356
11. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., and Gage, F. H. (2010) Mechanisms underlying inflammation in neurodegeneration Cell 140, 918-934
12. Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., and Herrmann, N. (2010) A meta-analysis of cytokines in Alzheimers disease Biol. Psychiatry 68, 930-941
13. Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C., and Breteler, M. M. (2004) Inflammatory proteins in plasma and the risk of dementia: the rotterdam study Arch. Neurol. 61, 668-672
14. Leoutsakos, J. M., Muthen, B. O., Breitner, J. C., and Lyketsos, C. G. (2012) Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimers Disease Anti-inflammatory Prevention Trial Int. J. Geriatr. Psychiatry 27, 364-374
15. McGeer, P. L., Schulzer, M., and McGeer, E. G. (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimers disease: a review of 17 epidemiologic studies Neurology 47, 425-432
16. Vlad, S. C., Miller, D. R., Kowall, N. W., and Felson, D. T. (2008) Protective effects of NSAIDs on the development of Alzheimer disease Neurology 70, 1672-1677
17. Shie, F. S. and Woltjer, R. L. (2007) Manipulation of microglial activation as a therapeutic strategy in Alzheimers disease Curr. Med. Chem. 14, 2865-2871
18. Yokokura, M., Mori, N., Yagi, S., Yoshikawa, E., Kikuchi, M., Yoshihara, Y., Wakuda, T., Sugihara, G., Takebayashi, K., Suda, S., Iwata, Y., Ueki, T., Tsuchiya, K. J., Suzuki, K., Nakamura, K., and Ouchi, Y. (2011) In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimers disease Eur. J. Nucl. Med. Mol. Imaging 38, 343-351
19. Heneka, M. T., Kummer, M. P., and Latz, E. (2014) Innate immune activation in neurodegenerative disease Nat. Rev. Immunol. 14, 463-477
20. Carpentieri, A., Diaz de Barboza, G., Areco, V., Peralta Lopez, M., and Tolosa de Talamoni, N. (2012) New perspectives in melatonin uses Pharmacol. Res. 65, 437-444
21. Rosales-Corral, S. A., Acuna-Castroviejo, D., Coto-Montes, A., Boga, J. A., Manchester, L. C., Fuentes-Broto, L., Korkmaz, A., Ma, S., Tan, D. X., and Reiter, R. J. (2012) Alzheimers disease: pathological mechanisms and the beneficial role of melatonin J. Pineal Res. 52, 167-202
22. Hatcher, H., Planalp, R., Cho, J., Torti, F. M., and Torti, S. V. (2008) Curcumin: from ancient medicine to current clinical trials Cell. Mol. Life Sci. 65, 1631-1652
23. Esatbeyoglu, T., Huebbe, P., Ernst, I. M., Chin, D., Wagner, A. E., and Rimbach, G. (2012) Curcumin-from molecule to biological function Angew. Chem., Int. Ed. 51, 5308-5332
24. Butterfield, D. A., Griffin, S., Munch, G., and Pasinetti, G. M. (2002) Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimers disease brain exists J. Alzheimers Dis. 4, 193-201
25. Lambert, J. C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., Tavernier, B., Letenneur, L., Bettens, K., Berr, C., Pasquier, F., Fievet, N., Barberger-Gateau, P., Engelborghs, S., De Deyn, P., Mateo, I., Franck, A., Helisalmi, S., Porcellini, E., Hanon, O., de Pancorbo, M. M., Lendon, C., Dufouil, C., Jaillard, C., Leveillard, T., Alvarez, V., Bosco, P., Mancuso, M., Panza, F., Nacmias, B., Bossu, P., Piccardi, P., Annoni, G., Seripa, D., Galimberti, D., Hannequin, D., Licastro, F., Soininen, H., Ritchie, K., Blanche, H., Dartigues, J. F., Tzourio, C., Gut, I., Van Broeckhoven, C., Alperovitch, A., Lathrop, M., and Amouyel, P. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimers disease Nat. Genet. 41, 1094-1099
26. Karch, C. M. and Goate, A. M. (2015) Alzheimers disease risk genes and mechanisms of disease pathogenesis Biol. Psychiatry 77, 43-51
27. Greenough, M. A., Camakaris, J., and Bush, A. I. (2013) Metal dyshomeostasis and oxidative stress in Alzheimers disease Neurochem. Int. 62, 540-555
28. Smith, D. G., Cappai, R., and Barnham, K. J. (2007) The redox chemistry of the Alzheimers disease amyloid beta peptide Biochim. Biophys. Acta 1768, 1976-1990
29. Tabner, B. J., Turnbull, S., El-Agnaf, O. M., and Allsop, D. (2002) Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimers disease and Parkinsons disease Free Radical Biol. Med. 32, 1076-1083
30. Wang, X., Wang, W., Li, L., Perry, G., Lee, H. G., and Zhu, X. (2014) Oxidative stress and mitochondrial dysfunction in Alzheimers disease Biochim. Biophys. Acta 1842, 1240-1247
31. Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., Rossor, M., and Brooks, D. J. (2008) Microglia, amyloid, and cognition in Alzheimers disease: an [11C](R)PK11195-PET and [11C]PIB-PET study Neurobiol. Dis. 32, 412-419
32. Narayan, P., Holmstrom, K. M., Kim, D. H., Whitcomb, D. J., Wilson, M. R., St. George-Hyslop, P., Wood, N. W., Dobson, C. M., Cho, K., Abramov, A. Y., and Klenerman, D. (2014) Rare individual amyloid-beta oligomers act on astrocytes to initiate neuronal damage Biochemistry 53, 2442-2453
33. Angelova, P. R. and Abramov, A. Y. (2014) Interaction of neurons and astrocytes underlies the mechanism of Abeta-induced neurotoxicity Biochem. Soc. Trans. 42, 1286-1290
34. Zempel, H. and Mandelkow, E. M. (2012) Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton Neurodegener. Dis. 10, 64-72
35. Clare, R., King, V. G., Wirenfeldt, M., and Vinters, H. V. (2010) Synapse loss in dementias J. Neurosci. Res. 88, 2083-2090
36. Dong, H., Martin, M. V., Chambers, S., and Csernansky, J. G. (2007) Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice J. Comp. Neurol. 500, 311-321
37. Arendt, T. (2009) Synaptic degeneration in Alzheimers disease Acta Neuropathol. 118, 167-179
38. DeKosky, S. T. and Scheff, S. W. (1990) Synapse loss in frontal cortex biopsies in Alzheimers disease: correlation with cognitive severity Ann. Neurol. 27, 457-464
39. Sze, C. I., Troncoso, J. C., Kawas, C., Mouton, P., Price, D. L., and Martin, L. J. (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease J. Neuropathol. Exp. Neurol. 56, 933-944
40. Bancher, C., Jellinger, K., Lassmann, H., Fischer, P., and Leblhuber, F. (1996) Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia Eur. Arch. Psychiatry Clin. Neurosci. 246, 137-146
41. Klein, W. L. (2013) Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimers disease? J. Alzheimers Dis. 33, S49-65
42. Selkoe, D. J. (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav. Brain Res. 192, 106-113
43. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration Proc. Natl. Acad. Sci. U.S.A. 108, 5819-5824
44. Ondrejcak, T., Klyubin, I., Hu, N. W., Barry, A. E., Cullen, W. K., and Rowan, M. J. (2010) Alzheimers disease amyloid beta-protein and synaptic function NeuroMol. Med. 12, 13-26
45. Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., Kurz, C., Leuner, K., and Muller, W. E. (2012) Mitochondrial dysfunction-a pharmacological target in Alzheimers disease Mol. Neurobiol. 46, 136-150
46. Pedros, I., Petrov, D., Allgaier, M., Sureda, F., Barroso, E., Beas-Zarate, C., Auladell, C., Pallas, M., Vazquez-Carrera, M., Casadesus, G., Folch, J., and Camins, A. (2014) Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimers disease Biochim. Biophys. Acta 1842, 1556-1566
47. Hauptmann, S., Scherping, I., Drose, S., Brandt, U., Schulz, K. L., Jendrach, M., Leuner, K., Eckert, A., and Muller, W. E. (2009) Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice Neurobiol. Aging 30, 1574-1586
48. Ayoub, A. E. and Salm, A. K. (2003) Increased morphological diversity of microglia in the activated hypothalamic supraoptic nucleus J. Neurosci. 23, 7759-7766
49. Yamada, J. and Jinno, S. (2013) Novel objective classification of reactive microglia following hypoglossal axotomy using hierarchical cluster analysis J. Comp. Neurol. 521, 1184-1201